Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

NCT05918302 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

170

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumors
Lung Neuroendocrine Neoplasm
Thymus Neoplasms

Interventions

DRUG: 177Lu-edotreotide
DRUG: Everolimus

Sponsor

Grupo Espanol de Tumores Neuroendocrinos

Collaborators

[object Object]
[object Object]